Objectives Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that
affects multiple organ systems. Belimumab, a targeted human monoclonal antibody, binds to …

Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab
is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been …

Safety data were pooled and analyzed from one phase 2 and two phase 3 double-blind,
placebo-controlled, repeat-dose systemic lupus erythematosus (SLE) trials of belimumab 1 …

BACKGROUND: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating
protein, was the first biologic agent approved for, and the first drug approved in 55 years for …

Introduction: Belimumab is a fully humanised mAb against B lymphocyte stimulator (B-LyS).
It is the first biological drug to be licensed and approved by the US FDA and the European …

Background Belimumab is the first antibody drug approved for systemic lupus
erythematosus (SLE), and is a fully human monoclonal antibody that inhibits soluble B …

Introduction Belimumab is a recombinant human monoclonal antibody that binds to soluble
B-lymphocyte stimulator and inhibits its biological activity. Since receiving approvals for the …

Belimumab (Benlysta®), a human immunoglobulin (Ig) G1λ monoclonal antibody targeting B
lymphocyte stimulator, is effective as an add-on to standard therapy in patients with active …

Introduction The real-world effectiveness of belimumab for systemic lupus erythematosus
(SLE) in six countries was evaluated in the OBSErve program. The aim of this post hoc …

Introduction: In 2011, Belimumab, a fully humanized monoclonal antibody against B
lymphocyte stimulator, became the first biological agent to be licensed by the United States …